Pramlintide, an injectable adjunct to mealtime insulin in diabetes, produces its glucose-lowering effect by mimicking which endogenous hormone?
- A Glucagon-like peptide-1 secreted by L cells of the ileum
- B Amylin, co-secreted with insulin from beta cells, delaying gastric emptying and suppressing postprandial glucagon ✓
- C Glucose-dependent insulinotropic peptide released from duodenal K cells
- D Somatostatin from pancreatic delta cells
Correct answer: B. Amylin, co-secreted with insulin from beta cells, delaying gastric emptying and suppressing postprandial glucagon
Explanation
Pramlintide is a synthetic analog of amylin, the peptide co-secreted with insulin by beta cells that is deficient in type 1 diabetes. It slows gastric emptying, suppresses inappropriate postprandial glucagon secretion and promotes satiety, reducing postprandial excursions. It is not a GLP-1 or GIP mimetic, though its gastric effects overlap with incretin actions, and somatostatin analogs such as octreotide are used for different indications entirely.
Reference: Katzung Basic and Clinical Pharmacology, 16th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.